Attovia Therapeutics Launches with $60M Series A Financing to Unlock Novel Biparatopic Nanobody

Fremont, CA, June 20, 2023 (Globe Newswire) -- Alamar Biosciences and Frazier Life Sciences join forces to establish Attovia Therapeutics, a groundbreaking company focused on creating a pipeline of biotherapeutics for immune-mediated diseases and cancer using the innovative Attobody™ biparatopic nanobody platform. With a successful $60 million Series A financing round, led by Frazier and supported by venBio and Illumina Ventures, Attovia aims to achieve clinical proof-of-concept and expand the capabilities of its core technology.

Read full article here.